The US Food and Drug Administration (:FDA) recently granted approval to Amgen’s (AMGN) Prolia (denosumab) for an additional indication. Prolia can now be used as a treatment for increasing bone mass ...

(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - ...

Sandoz is introducing Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz, the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of Amgen’s ...

Xgeva and Prolia are two drugs Amgen investors need to keep an eye on. Thanks to label expansion that permitted wider use of the drugs, they've been Amgen's fastest-growing products this past year.

Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will permit it to market drugs in the United States that are biosimilars to Amgen's Prolia and Xgeva. Both medications use ...

The FINANCIAL — Amgen on July 31 announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia (denosumab) for the treatment ...

Oct 28 (Reuters) - Amgen Inc (AMGN.O), opens new tab on Wednesday said third-quarter adjusted profit rose 17% due to stronger sales of drugs such as osteoporosis treatment Prolia and psoriasis ...

Amgen is committed to supporting patient access to important medicines through innovative programs including our newly established commercial co-pay program for XGEVA, the Safety Net Foundation, which ...